secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0000950170-25-086284
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics shareholders elect three Class I directors, ratify EY
------------------------------------------------------------------------

- David Campbell, Ron Barrett, and Winston Kung elected Class I directors with >42M votes each.
- Ernst & Young ratified as auditor for FY2025: 56.15M for, 27K against.
- Advisory vote on executive compensation approved: 53.2M for, 1.15M against.
- Advisory vote favors 1-year frequency for future say-on-pay votes: 54.0M for 1 year.
- 59.2M shares outstanding, 56.2M present at meeting; broker non-votes of 1.87M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025086284/0000950170-25-086284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025086284/janx-20250611.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-086284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer